NCT00644488View on ClinicalTrials.gov

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Prostate Cancer
Interventions
DRUG

BMS-641988 (AR#2)

Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks

Trial Locations (3)

1358550

Local Institution, Koto-Ku

3501298

Local Institution, Hidaka

431-3192

Local Institution, Hamamatsu

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00644488 - A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter